Search

M2 PRESSWIRE-January 15, 2025-: Retinitis Pigmentosa Pipeline Assessment 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics, ID Pharma (C)1994-2025 [...]

M2 PRESSWIRE-January 15, 2025-: Acute Kidney Injury Pipeline Analysis 2024: FDA Approvals, Emerging Therapies, and Key Companies involved by DelveInsight | Astellas Pharma, Amniotics, Guard Therapeutics, RegeneRx Biopharma, Cerenis (C)1994-2025 [...]

First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints Daily oral NIM-1324 treatment confirmed as well-tolerated and safe with no dose-limiting toxicities Oral treatment with NIM-1324 validated to [...]

M2 PRESSWIRE-January 7, 2025-: Ascites Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | YZY Biopharma, Healthgen Biotech, Grifols Therapeutics, Versantis (C)1994-2025 M2 COMMUNICATIONS [...]

M2 PRESSWIRE-December 20, 2024-: Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp [...]

M2 PRESSWIRE-November 26, 2024-: Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic (C)1994-2024 M2 COMMUNICATIONS RDATE:26112024 Women - especially teen girls and young women [...]

ATHENS, Ga. & SAN JOSE, Calif. -- Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune [...]

* Phase 2a study to evaluate safety and immunogenicity of a booster dose of influenza vaccine candidate OVX836, three to five years after initial administration * Enrollment of over 150 [...]

MUMBAI, India & HYDERABAD, India -- PopVax, an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using machine learning-enabled computational protein design, is pleased to announce that it [...]

Hansa Biopharma and Genethon, a company focusing on gene therapy research and development for rare genetic diseases, reported initiation of GNT-018-IDES, a Phase 2 trial in patients with Crigler-Najjar syndrome [...]

Blue Lake Biotechnology, a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, and [...]

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, [...]

NORDIC BUSINESS REPORT-December 3, 2024-Genethon and Hansa Biopharma initiate Phase 2 trial for Crigler-Najjar syndrome (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Swedish biopharmaceutical company Hansa Biopharma (STO:HNSA) and Genethon, a developer of [...]

(GLOBE NEWSWIRE via COMTEX) -- - The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of [...]

M2 PRESSWIRE-October 25, 2024-: Triple Negative Breast Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular (C)1994-2024 [...]

M2 PRESSWIRE-October 24, 2024-: Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics (C)1994-2024 [...]

Stockholm: Karolinska Development AB has issued the following news release: Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines, has presented positive clinical safety and immunogenicity [...]

M2 PRESSWIRE-October 22, 2024-: Primary Hyperoxyaluria Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight | Dicerna Pharma, Allena Pharma, Genentech, Biocode, Alnylum (C)1994-2024 M2 [...]

M2 PRESSWIRE-October 21, 2024-: Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc [...]

- Novel Investigational Combination Regimen is Advancing to Phase 3 and has the Potential to Become the First Weekly Oral HIV Treatment - FOSTER CITY, Calif., & RAHWAY, N.J. -- [...]

M2 PRESSWIRE-October 15, 2024-: Pressure Ulcers Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Xantho Biotechnology, Biocomposites Ltd, RegeneRx Biopharma, B. Braun (C)1994-2024 [...]

M2 PRESSWIRE-October 9, 2024-: Hepatitis B Virus Infection Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, and Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:09102024 Hepatitis B Virus [...]

M2 PRESSWIRE-October 2, 2024-: Multiple Sclerosis Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion, Bayer, Acorda (C)1994-2024 M2 [...]

M2 PRESSWIRE-October 2, 2024-: Irritable Bowel Syndrome Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | P4 Microbiome, Biomica, Invea Therapeutics, RaQualia Pharma, RedHill Biopharma (C)1994-2024 M2 [...]

M2 PRESSWIRE-October 1, 2024-: Alpha Thalassemia Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma (C)1994-2024 M2 COMMUNICATIONS RDATE:01102024 (Las [...]

* New preclinical data demonstrate potential for precision-engineered B cell medicines ('BCMs') to produce active and sustained levels of tissue-nonspecific alkaline phosphatase ('ALP') * Data presented at the American Society [...]

NEW YORK -- Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced the completion of enrollment of its U.S. Phase [...]

HOUSTON -- Kiromic BioPharma, Inc. (OTCQB: KRBP) ('Kiromic' or the 'Company') announces that the University of Arizona Cancer Center (UACC) has been activated as the fifth clinical trial site in [...]

HOUSTON -- Kiromic BioPharma, Inc. (OTCQB: KRBP) ('Kiromic' or the 'Company') announced today that the Deltacel-01 Safety Monitoring Committee (SMC) has unanimously voted in favor of proceeding with the expansion [...]

M2 PRESSWIRE-August 29, 2024-: T-Cell Lymphoma Pipeline Assessment 2024 | Clinical Trials, Latest Approvals, Treatment Outlook, Competitive Landscape, Key Companies | Soligenix, CStone Pharmaceuticals, Genor Biopharma, Innate Pharm (C)1994-2024 M2 [...]

(GLOBE NEWSWIRE via COMTEX) -- - Novel JEL(TM) Technology for Periocular Administration COSTA MESA, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that [...]

Oslo: Lytix Biopharma AS has issued the following news release: Lytix Biopharma ('Lytix') announces that its Nasdaq-listed licensing partner Verrica Pharmaceuticals reports positive top-line Phase II results from its study [...]

On track to initiate Part 2 in September HOUSTON -- Kiromic BioPharma, Inc. (OTCQB: KRBP) ('Kiromic' or the 'Company') reports interim results near the completion of Part 1 of its [...]

Oslo: Ultimovacs ASA has issued the following news release: Ultimovacs ASA ('Ultimovacs') (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that an update from the Phase [...]

Kiromic BioPharma reported that the Deltacel-01 Safety Monitoring Committee (SMC) has unanimously voted in favor of proceeding with the expansion phase of the Deltacel-01 clinical trial. The company said the [...]

Key Highlights: * Bio-Thera Solutions, Ltd. announced results from Phase 3 clinical study on BAT1806/BIIB800 biosimilar to tocilizumab. * TP2 analysis showed comparable clinical efficacy, safety, immunogenicity, and PK after [...]

* 10 of 12 patients treated in HER2 expressing solid tumor Phase 1b trial were breast cancer patients * Dose selected for ongoing Phase 2b clinical trial in Osteosarcoma was [...]

- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor - No statistically significant differences were demonstrated between any dose [...]

OXFORD, England & CAMBRIDGE, Mass. -- SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced today the completion of [...]

M2 PRESSWIRE-July 10, 2024-: ANCA Vasculitis Pipeline Insights 2024: Therapies, Clinical Trials, and Clinical Trials by DelveInsight | Vifor Pharma, GlaxoSmithKline, Amgen, Genentech, Pfizer, ChemoCentryx, Biogen (C)1994-2024 M2 COMMUNICATIONS RDATE:10072024 [...]

M2 PRESSWIRE-July 9, 2024-: Urticaria Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Sanofi, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPhar (C)1994-2024 M2 [...]

M2 PRESSWIRE-July 4, 2024-: Primary Hyperoxyaluria Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Dicerna Pharma, Allena Pharma, Genentech, Biocode, Alnylum (C)1994-2024 M2 [...]

M2 PRESSWIRE-July 2, 2024-: Chronic Refractory Cough Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight | Genentech, Trevi Therapeutics, Guangdong Hengrui Pharma, Ltd, Bellus Health, Merck (C)1994-2024 M2 [...]

M2 PRESSWIRE-July 1, 2024-: Multiple Sclerosis Clinical Trials Assessment 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA and Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:01072024 Multiple Sclerosis Companies are TG [...]

M2 PRESSWIRE-June 28, 2024-: Hyperoxaluria Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies by DelveInsight | Alnylam Pharma, Genentech, Dicerna Pharma, Pfizer Inc., Zhejiang Tianxin Pharma, Wuxi Further Pharma (C)1994-2024 [...]

M2 PRESSWIRE-June 28, 2024-: Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial (C)1994-2024 M2 COMMUNICATIONS RDATE:28062024 Dynavax Technologies Corporation (Nasdaq: DVAX), a California-based commercial-stage biopharmaceutical company, announced on [...]

M2 PRESSWIRE-June 24, 2024-: Ulcerative Colitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:21062024 DelveInsight's, 'Ulcerative Colitis Pipeline Insight 2024' report provides [...]

M2 PRESSWIRE-June 21, 2024-: Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insights | Alexza Pharma, Xenon Pharma, GW Pharma, Equilibre Biopharma, Takeda Pharma, Abide therapeutics, Otsuka pharma (C)1994-2024 [...]

Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial's Second Cohort [...]

M2 PRESSWIRE-June 19, 2024-: Spinocerebellar Ataxias Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Biogen Inc, Ionis Pharma, BioXcel Corp, Celavie Biosciences [...]